**Ariceum Therapeutics** (Ariceum), a private biotech company specializing in radiopharmaceutical development for diagnosing and treating challenging cancer types, alongside **Eckert & Ziegler**, a leading global distributor of medical isotopes for various applications, have officially entered into a worldwide supply pact for Actinium-225 (Ac-225) and Lutetium-177 (Lu-177) radioisotopes.
Responding to the limited global availability and the intricate production process of Ac-225, amid rising demand, the collaboration marks a pivotal advancement for Ariceum to enhance their innovative radiopharmaceutical pipeline projects.
Per the agreement, Eckert & Ziegler is tasked with providing Ariceum the required amounts of non-carrier-added (n.c.a.) Ac-225 and Lu-177. These radionuclides will serve to label Ariceum’s innovative leading radiopharmaceutical agent (SS0110) satoreotide aimed at targeting complex cancer cases in upcoming clinical trials as well as during subsequent commercial efforts. The agreement also encompasses further extension to additional drugs and radionuclide usage in preparation for future market endeavors.
_Mr. Manfred Rüdiger, CEO of Ariceum Therapeutics, remarked:_ “This critical global supply partnership with Eckert & Ziegler for n.c.a. Ac-225 and Lu-177 secures a steady supply of radionuclide isotopes essential for our clinical trials. We anticipate working closely with the Eckert & Ziegler team to establish a dependable supply chain and consistently provide targeted theranostic solutions for patients facing severe cancer challenges. Our leading radiopharmaceutical, satoreotide, stands out as an innovative antagonist targeting somatostatin receptor 2 (SSTR2), soon entering clinical trials for small cell lung cancer and Merkel Cell Carcinoma.”
_Dr. Harald Hasselmann, CEO of Eckert & Ziegler, stated:_ “By partnering with Ariceum, we align with their mission to create groundbreaking radiopharmaceuticals that benefit patients. Our initiation of Ac-225 production and the European approval of Theralugand exemplify our commitment to easing the scarcity of premium radioisotopes. Our objective is to propel forward novel treatments through clinical trials and beyond, thereby playing an instrumental role in life-saving endeavors.”
**About the Companies:**
**Ariceum Therapeutics**: This private clinical-stage company is committed to diagnosing and accurately treating specific neuroendocrine and formidable cancer forms.
**Eckert & Ziegler SE**: With over 1,000 staff, this company is a prominent authority in isotopic elements for nuclear medicine and radiation therapy, providing comprehensive services across the radiopharmaceutical industry, from initiation to production and distribution.